Pharmaceutical compositions for the treatment or prevention of osteoporosis
Abstract
Pharmaceutical compositions for the treatment or prevention of osteoporosis. Oral pharmaceutical composition, in the form of chewable tablets, effervescent granules or effervescent tablets, stable and with improved technical and organoleptic characteristics, containing a salt of fluoride ions, vitamin D and elemental calcium in salt form, together with suitable amounts of pharmaceutically acceptable excipients , useful for the treatment or prevention of osteoporosis or other bone diseases, characterized by the loss of bone mass.
Term
Term ended
Projected expiry passed 4 January 2022, 4.7 years ago.
- Priority and filed
- Published
- Projected expiry
- Today
23 claims: 21 independent, 2 dependent
- 1ES 2 192 136 A1 REIVINDICACIONES 1. Composicióon farmacóeutica oral, estable y con caracterósticas tóecnicas y organolóepticas mejoradas, que comprende:- entre 100 U.I. y 4000 U.I de vitamina D;- entre 500 y 600 mg de calcio elemental;- entre 2 y 15 mg de iones fluoruro;caracterizada porque ademaós comprende: - entre 0.1 y 1 % de un edulcorante de sabor intenso seleccionado entre el grupo formado por aspartamo, sacarina sóodica, ciclamato sóodico, acesulfamo potaósico y sus mezclas.
- 2Composicioón seguón la reivindicacióon 1, caracterizada porque los iones fluoruro provienen de una sal de fluoruro seleccionada entre el grupo formado por fluoruro soódico, monofluorofosfato sóodico y sus mezclas.
- 3Composicióon seguón cualquiera de las reivindicaciones anteriores, caracterizada porque el fluoruro sóodico se ha granulado previamente con un material gastrorresistente que permite una liberacioón sostenida del principio activo de tal forma que se consigue retrasar suficientemente en el tiempo la liberacióon del principio activo, con el fin de evitar la coexistencia de iones fluoruro e iones calcio y ademóas se consigue una liberacióon sostenida de tal modo que se evitan picos plasmóaticos de iones fluoruro que excedan los niveles tóoxicos para óestos.
- 4Composicióon seguón la reivindicacióon anterior, caracterizada porque el material utilizado para la granulacioón del fluoruro soódico se selecciona entre el grupo formado por derivados de celulosa, polómeros acrólicos metacrólicos, behenato de glicerilo y sus mezclas.
- 5Composicioón seguón cualquiera de las reivindicaciones anteriores 3 a 4, caracterizada porque el material utilizado para la granulacióon del fluoruro soódico es etilcelulosa.
- 6Composicióon seguón cualquiera de las reivindicaciones anteriores, caracterizada porque el calcio elemental proviene de una sal de calcio elegida entre el grupo formado por carbonato de calcio, pidolato de calcio, lactato de calcio, citrato de calcio, gluconato de calcio, cloruro de calcio, glucoheptonato de calcio, fosfato de calcio, glicerofosfato de calcio, y sus mezclas.
- 7Composicioón seguón cualquiera de las reivindicaciones anteriores, caracterizada porque la sal cóalcica utilizada se selecciona entre el grupo formado por carbonato de calcio, gluconato de calcio, lactato de calcio, citrato de calcio y sus mezclas.
- 8Composicioón seguón cualquiera de las reivindicaciones anteriores, caracterizada porque la sal cóalcica utilizada es carbonato de calcio.
- 9Composicioón seguón cualquiera de las reivindicaciones anteriores, caracterizada porque la sal cóalcica se ha granulado previamente con un aglutinante seleccionado entre el grupo formado por maltodextrinas y almidoón pregelatinizado.
- 10Composicioón seguón cualquiera de las reivindicaciones anteriores, caracterizada porque ademaós comprende entre 0.01 y 1 % del peso de la composicioón, de uno o varios aromas seleccionados entre el grupo formado por esencia de naranja, limoón, fresa, esencias de frutas del bosque, menta y anós.
- 11Composicióon seguón cualquiera de las reivindicaciones anteriores, caracterizada porque ademaós comprende entre 1 y 30% del peso de la composicióon de un edulcorante de sabor poco intenso.
- 12Composicioón seguón la reivindicacioón 11, caracterizada porque el edulcorante de sabor poco intenso se selecciona entre el grupo formado por sorbitol, manitol, xilitol, fructosa, maltosa, maltitol, lactitol, y sus mezclas.
- 13Composicióon seguón cualquiera de las reivindicaciones anteriores 1 a 12, caracterizada porque ademaós comprende entre 1 y 12 % del peso total de la composicióon, de un excipiente con caracterósticas ES 2 192 136 A1 disgregantes y aglutinantes seleccionado entre el grupo formado por crospovidona, croscarmelosa y derivados de celulosa.
- 14Composicioén seguén la reivindicaciéon 13, caracterizada porque el derivado de celulosa es hidroxipropilcelulosa.
- 15Composicioén seguén cualquiera de las reivindicaciones anteriores 1 a 14, caracterizada porque contiene ademéas éacido cétrico.
- 16Composiciéon seguén cualquiera de las reivindicaciones 1 a 10, caracterizada porque contiene ademéas uno o varios agentes liberadores de CO2 seleccionados entre el grupo formado por carbonatos de metales alcalinos o bicarbonatos de metales alcalinos, junto con un agente inductor de la liberacioén del CO2 por el anterior, seleccionado entre el grupo formado por éacidos orgaénicos, sales éacidas de éacidos orgaénicos y sus mezclas.
- 17Composiciéon seguén la reivindicaciéon 16, caracterizada porque contiene entre 100 y 400 mg de un carbonato o bicarbonato de metal alcalino y entre 200 y 500 mg de un éacido orgéanico o su sal éacida.
- 18Composiciéon seguén las reivindicaciones 16 a 17, caracterizada porque el agente liberador de CO2 es bicarbonato séodico.
- 19Composiciéon seguén las reivindicaciones 16 a 18, caracterizada porque el agente inductor de la liberacioén de CO2 se selecciona entre el grupo formado por éacido tartéarico, aécido méalico, éacido fumaérico, éacido succénico, éacido ascéorbico, éacido maleico, aécido cétrico, sales aécidas de los anteriores y sus mezclas.
- 20Composiciéon seguén las reivindicaciones 16 a 19, caracterizada porque el agente inductor de la liberacioén de CO2 es éacido cétrico.
- 21Composiciéon seguén las reivindicaciones 16 a 20, caracterizada porque contiene entre 100 y 400 mg de bicarbonato soédico y entre 200 y 500 mg de aécido cétrico.
- 22Composicioén farmacéeutica oral, en forma de comprimidos masticables, granulados efervescentes o comprimidos efervescentes, estable y con caracterésticas téecnicas y organoléepticas mejoradas, que comprende:- entre 100 U.I. y 4000 U.I de vitamina D;- entre 500 y 600 mg de calcio elemental;- entre 75 y 100 mg de monofluorofosfato soédico;caracterizada porque ademaés comprende: - entre 0.1 y 1 % de un edulcorante de sabor intenso seleccionado entre el grupo formado por aspartamo, sacarina séodica, ciclamato soédico y sus mezclas.
- 23Composicioén seguén la reivindicaciéon 22, para su uso en la preparacioén de un medicamento para el tratamiento o prevenciéon de la osteoporosis u otras enfermedades éoseas caracterizadas por la péerdida de masa oésea.
Independent claims23
371 paragraphs in 16 sections, as filed
ES 2 192 136 A1
DESCRIPTION
Pharmaceutical compositions for the treatment or prevention of osteoporosis.
The present invention relates to new pharmaceutical compositions for the treatment or prevention of osteoporosis or other bone diseases characterized by loss of bone mass. More particularly, this invention relates to oral pharmaceutical compositions, in the form of chewable tablets, effervescent granules or effervescent tablets containing a salt of fluoride ions, vitamin D and elemental calcium (in the form of a salt) together with suitable amounts of pharmaceutically acceptable excipients, Useful for the treatment or prevention of osteoporosis or other bone diseases characterized by loss of bone mass.
Prior state of the art
Osteoporosis is the most common alteration of the skeleton, it is defined as the decrease in bone mass per unit of volume in relation to what is considered normal for a certain age, sex and race, with the orgaonic structure and mineral content of the bone being normal. bone. Osteoporosis can be secondary (due to different known pathologies) and primary or idiopathic, being in this case of two different types: Type I characterized by loss of trabecular bone and Type II characterized by loss of cortical bone.
The mechanism by which bone loss occurs in idiopathic osteoporosis encompasses an imbalance between formation and resorption, where osteoclasts are responsible for bone resorption, a process that is followed by the formation of bone mass by osteoblasts. Idiopathic osteoporosis is caused either by an excess of osteoclast activity or by a decrease in osteoblast activity.
Fluoride is a known inducer of osteoblastic proliferation, being sodium fluoride (FNa) and sodium monofluorophosphate (MFP) the only clonically acceptable salts.
There are various theories regarding the mechanism of action by which fluoride favors the formation of bone mass, the most accepted being the one proposed by Lau KHW (Metabolism, 1989), according to which fluoride, at mitogenic concentrations, selectively inhibits the activity of the phosphotyrosyl phosphatase enzyme in osteoblasts and stimulates their proliferation and bone formation.
Patent application EP0455503 describes a composition for the treatment of diseases related to bone loss, containing sodium monofluorophosphate and an estrogen.
In PCT application WO 97/16193 a pharmaceutical composition for the treatment of osteoporosis is described containing the compound 1a-fluoro-25-hydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol.
FNa is absorbed mainly in the stomach, and it could be absorbed, although to a lesser extent, in the beginning of the small intestine; the FNa in the acidic environment of the stomach is transformed into fluorhydric acid, which is the cause of the harmful effects, in the form of gaostric irritability, caused by the administration of FNa. On the other hand, the time in which the maximum concentration at the plasma level of sodium fluoride is reached is approximately 0.56 h, which indicates the rapid absorption of this active principle. Furthermore, FNa is incompatible with Ca compounds<sup>2+</sup> since the formation of coalcium fluoride occurs, which is very poorly soluble, and therefore reduces the bioavailability of fluoride and calcium. The main disadvantage of the MFP is the bitter saline taste that is difficult to mask, although the chemical instability in solution at a pH lower than 1.5 is also noteworthy, which translates into its hydrolysis to fluoride and orthophosphate.
The optimal therapeutic range for fluoride ions is 10 to 50 mg / day for an adult human. The MFP dose normally used in bioavailability studies is equivalent to 13.2 mg or 10.5 mg of fluoride per tablet. It is advisable not to administer more than 25 mg of fluoride / day. This dose has been established on the basis of the fact that it has been observed that when doses of 60 mg of FNa / doa are used, there is an exchange of calcium between the cortical to trabecular bone and the formation of an abnormal bone occurs.
The use of calcium and vitamin D as a complement in the therapy used in the treatment of osteoporosis is widely known. Calcium is the predominant mineral in bone and its absorption is facilitated by the presence of vitamin D.
ES 2 192 136 A1
In patent application WO 96/09036 combinations of vitamin D and calcium carbonate are described for the treatment of osteoporosis.
In WO 92/19251 nutritional supplements are described containing a calcium salt and vitamin D, and optionally containing a estrogen.
Osteomalacia is one of the most important problems in long-term administration of fluoride, because the calcification of the newly formed bone is deficient, which increases its crystallinity and decreases its elasticity. Therefore, the use of calcium and vitamin D supplements is considered essential in order to normalize bone mineralization and avoid the appearance of osteomalacia.
The term vitamin D includes vitamin D, cholecalciferol (D3), ergocalciferol (D2), and their biologically active metabolites and precursors. These promote the intestinal absorption of calcium, contribute to the regulation of calcium in plasma by acting in the process of formation and resorption and stimulate the reabsorption of calcium in the kidney.
The combination of poor gastrointestinal calcium absorption and a deficient intake of calcium increases the risk of a negative calcium balance in older people. As a consequence, PTH secretion is increased, which stimulates bone resorption. Calcium supplementation reduces serum PTH levels, avoiding excessive loss of bone mass associated with resorption.
The recommended amount of calcium varies depending on the authors and the salt in which it is found. In patients treated with sodium fluoride, elemental calcium (1000-1500 mg / day), calcium carbonate, lactate or gluconate (1000 mg of Ca<sup>2+</sup>/ day) and calcium citrate (800 mg of Ca<sup>2+</sup>/ day). When calcium is associated with MFP, the most commonly used salts are calcium carbonate (1000-1500 mg of Ca<sup>2+</sup>/ day) and citrate and gluconate (500-1000 mg of Ca<sup>2+</sup> / day).
Vitamin D should not be administered in supraphysiological concentrations because it alters renal function, while excessively high doses increase the risk of stress fracture (in cortical bone) due to increased bone resorption, while intermediate doses do not increase resorption in treated patients. with fluoride. Therefore, the optimal amounts of vitamin D in treatment together with fluoride ranges from 200 IU / day to 8000 IU / day.
Although pharmaceutical compositions of calcium salts with cholecalciferol in the form of chewable tablets are known, this is not the case with pharmaceutical compositions of fluoride salts, due to the problems that the active principle involves in this type of formulation, as well as the phasic-chemical compatibility with The calcium.
There is a need for a vitamin-calcium-fluoride ion association that comprises, in a single and the same pharmaceutical form, an optimal relative dosage of vitamin D, calcium and fluoride for the treatment of osteoporosis or diseases related to bone loss. , thereby improving patient comfort and compliance, as well as reducing gastrointestinal side effects and those related to abnormal bone mineralization or osteomalacia resulting from long-term fluoride treatment.
Oral pharmaceutical forms such as effervescent granules, chewable tablets and effervescent tablets represent the most appropriate formulas to ensure a greater degree of compliance by the patient, especially in those who have swallowing difficulties or in elderly people, at the same time as obvious advantages over other pharmaceutical forms in terms of patient comfort.
The object of the present invention is oral pharmaceutical compositions, in the form of effervescent granules, chewable tablets and effervescent tablets, which contain as active principles fluoride ions, elemental calcium and vitamin D, together with suitable amounts of pharmaceutically acceptable excipients.
When the pharmaceutical composition object of the present invention is presented in the form of effervescent granules, this granules are usually packed in sachets with suitable technical characteristics for this purpose, thus optimizing its presentation and ensuring correct dosage by the user. patient.
ES 2 192 136 A1
Providing pharmaceutical forms with good palatability represents a great problem when we use effervescent or chewable oral pharmaceutical forms and where an active principle has an unpleasant taste (as is the case with sodium monofluorophosphate or sodium fluoride) and another, cealcium salt, is incorporated in a very important amount in the formulation and also has poor palatability characteristics.
In addition, other additional factors inherent to the formulation in the form of chewable tablets must be taken into account, such as good taste without bitter aftertaste, non-cloying taste, good chewiness, absence of guminess to avoid sticking to teeth or dentures, adequate friability values and hardness.
Explanation of the invention
The present invention solves the aforementioned problems of palatability, technical characteristics and stability, by providing a new oral pharmaceutical composition, comprising:
- between 100 IU and 4000 IU of vitamin D;
- between 500 and 600 mg of elemental calcium;
- between 2 and 15 mg of fluoride ions;
- between 0.1 and 1% of a sweetener with an intense flavor selected from the group consisting of aspartame, sodium saccharin, sodium cyclamate, acesulfame potassium and their mixtures;
together with adequate amounts of other pharmaceutically acceptable excipients, for the preparation of a medicament for the prevention or treatment of osteoporosis or other bone diseases characterized by loss of bone mass.
In a preferred embodiment, the fluoride ions come from a fluoride salt selected from sodium fluoride, sodium monofluorophosphate, and mixtures thereof.
When the fluoride salt selected is sodium fluoride, an appropriate technological treatment must be carried out to avoid physical contact between the calcium released by the calcium salt and the fluoride released by the sodium fluoride, since the formation of calcium fluoride will occur. which is very poorly soluble, and therefore will decrease the bioavailability of fluoride and calcium.
Since it is known in the state of the art that fluoride can be absorbed in the intestine, and in order to avoid irritation of the gastric mucosa produced by sodium fluoride, and its rapid absorption, which produces plasma ion peaks. fluoride that trigger rheumatic complications such as fluorosis, it is more appropriate to use a gastro-resistant coating of sodium fluoride, by using a material that modulates its release, delaying it in time sufficiently to avoid the formation of caloric fluoride. The sustained release of FNa must comply with the premises of sufficiently delaying the release of the active principle in time, in order to avoid the coexistence of fluoride ions and calcium ions, which will cause the formation of the insoluble salt of cealcium fluoride, decreasing this mode the bioavailability of both, and also should allow a sustained release so as to avoid plasma peaks of fluoride ions that exceed the toxic levels for them.
Therefore, the use of any suitable material for the sustained release of active principles is suitable for coating the FNa.
In a preferred embodiment of the present invention, the material used for coating the FNa is selected from the group consisting of cellulose derivatives, methacrylic acrylic polymers, glyceryl behenate and their mixtures.
In a more preferred embodiment, the cellulose derivative is selected from the group consisting of ethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, and methyl cellulose.
In a still more preferred embodiment the material used for coating the FNa is ethylcellulose.
ES 2 192 136 A1
In another preferred embodiment of the present invention, the fluoride ion salt used is sodium monofluorophosphate.
The calcium salt preferred in the present invention is selected from calcium carbonate, calcium pidolate, calcium lactate, calcium citrate, calcium gluconate, calcium chloride, calcium glucoheptonate, calcium glycerophosphate. , calcium phosphate and their mixtures.
In a preferred embodiment, the calcium salt used is selected from the group consisting of calcium carbonate, calcium gluconate, calcium lactate, calcium citrate, and mixtures thereof.
In a still preferred embodiment, the calcium salt used is calcium carbonate.
Optionally, the kaolic salt can be previously granulated with maltodextrins or with pregelatinized starch to favor its granulation, so that a raw material with adequate flow and compressibility characteristics is achieved.
The oral pharmaceutical compositions of the present invention are formulated as effervescent granules, effervescent tablets, or chewable tablets.
In a preferred embodiment, said pharmaceutical composition is formulated in the form of a tablet to chew and contains between 10 and 200 mg of choric acid.
Effervescent formulations generally include an agent capable of releasing CO2, such as alkali metal carbonates or bicarbonates, together with an agent that induces the release of CO2, such as orgaonic acids or their acid salts, which are present in solid form and may be present. formulated with the active principles and other excipients in the form of granules or tablets, without a premature release of CO2. Orgaonic acids such as tartaric acid, maolic acid, fumaoric acid, succonic acid, ascoorbic acid, maleic acid or choric acid are preferred.
In a preferred embodiment, said pharmaceutical composition is formulated in the form of an effervescent granule or tablet and contains between 100 and 400 mg of an alkali metal carbonate or bicarbonate and between 200 and 500 mg of an orgaonic acid or its acidic salt.
In a still preferred embodiment, said effervescent pharmaceutical composition contains between 100 and 400 mg of sodium bicarbonate and between 200 and 500 mg of choric acid.
The presence of the sweetener, accompanied by the flavoring, allows masking the bitter taste of sodium monofluorophosphate or fluoride, so that it is perfectly suitable for oral formulation, either as chewable tablets or as granules or effervescent tablets. Sweeteners provide a sweet taste, a pleasant and refreshing sensation in the mouth due to the fact that they have a negative heat of dissolution. Its presence in the formulation, when it comes to tablets, must comply with the premises of not reducing the compressibility of the mixture and allowing a reproducibility of the resistance to breakage fork, a crotic paraometer in the case of tablets.
In a preferred embodiment, the composition also contains a suitable amount of sweetener with a low intensity flavor that is selected between 1 and 30% of the weight of the composition, of one or more sweeteners selected from the group consisting of sorbitol, mannitol, xylitol, fructose. , maltose, maltitol, lactitol, and their mixtures; optionally accompanied by a suitable amount of flavoring, where the appropriate amount of flavoring is selected between 0.01 and 1% of the weight of the composition of one or more aromas selected from the group consisting of essence of orange, lemon, strawberry, fruit essences of the forest, mint and years.
In addition to the sweetener and flavoring, the presence of other pharmacoeutically acceptable excipients is necessary, excipients with disintegrating characteristics and binders being preferred, which gives the appropriate consistency to the tablet, being those of the crospovidone, croscarmellose and cellulose derivatives type.
In a preferred embodiment, the disintegrating-binder excipient is a cellulose derivative. In a still preferred embodiment, the cellulose derivative is hydroxypropyl cellulose.
The presence of choric acid contributes to masking the bitter taste of sodium monofluorophosphate or sodium fluoride, while acting as an effervescent disintegrant since saliva activates the
ES 2 192 136 A1 disintegration by effervescence in contact with the calcium salt. In the case of effervescent formulations, the presence of citric acid favors the release of CO<sub>2</sub> by the alkali metal carbonate or bicarbonate present in the formulation, thus achieving the desired effervescence effect.
The compositions of the present invention are surprisingly stable for long periods of time, at the same time that their phospho-chemical compatibility is favored, since it has been found that the kaolic salt in contact with the monofluorophosphate in an acidic medium similar to juice gaostric, acted as a buffering medium avoiding the hydrolysis of monofluorophosphate to fluoride and orthophosphate, therefore minimizing the gastric irritation by fluoride and the formation of the insoluble salt F2Ca, which led to a decrease in the bioavailability of the active principles fluoride and calcium.
The results are similar when we use FNa as a source of fluoride ions, since in addition to the buffering effect of the caolic salt it has been found that the previous granulation of the FNa with the gastro-resistant material, thus obtaining a sustained release of the active principle, allows to achieve that the liberation of fluoride ions is prolonged in time; In this way, it is avoided that they react with the calcium ions, released immediately in the acidic medium of the gaostric juice, and that are absorbed mainly in the duodenum, thus minimizing the formation of the insoluble salt F2Ca, avoiding a decrease in the bioavailability of the active principles fluoride and calcium.
When the pharmaceutical form is a tablet (either to chew or effervescent), it must meet certain technical characteristics of this type of formulation, such as the hardness and friability of the tablet. For which excipients have been selected that guarantee to maintain the constant hardness parameter over time. Non-hygroscopic excipients have been used, not only to avoid the tendency of the tablet to decrease its hardness over time, but also because they could drastically affect the stability of one of the active principles, vitamin D. Likewise, they have been avoided the use of excipients that lose moisture over time to avoid an increase in the hardness of the tablets.
The pharmaceutical compositions of the present invention (in the case of being formulated as chewing tablets) have adequate technical characteristics (low friability and hardness values), despite the limitation represented by the amount of excipients that can be added to the composition. , since only the amount of the active principles represents around 50-70% of the totality of it.
The pharmaceutical compositions of the present invention (in the case of being formulated as chewing tablets), present friability values even lower than those generally indicated for this type of pharmaceutical forms (around 34%).
Examples
The invention is illustrated with the following non-limiting examples:
Gastric compatibility test
The following test illustrates the compatibility of the formulation of two of the three active ingredients in the same pharmaceutical form without any type of incompatibility in the gastrointestinal tract.
Two of the three active principles are taken into account, the calcium salt and the fluoride ion salt, in this case sodium monofluorophosphate, since vitamin D is insoluble in aqueous media, using amounts in the same proportion as that used in formulations described herein (test samples).
The gaostric medium has an approximate pH of 1.16, so a solution with that pH is prepared at 37 ° C, the samples are kept with a slight agitation for two hours, a time that the gaostric digestion lasts under normal conditions. Sodium monofluorophosphate samples are used as a control (blank).
By means of a selective fluoride ion electrode, the initial value of free fluoride is quantified and subsequently hydrolysis is forced, in order to release the fluoride ions completely and to be able to quantify the total.
ES 2 192 136 A1
The results obtained for the sodium monofluorophosphate test are shown in Table I.
TABLE I
<td>Show</td><td>% Recovery (Before hydrolysis)</td><td>% Recovery (After hydrolysis)</td><td>initial pH</td>
<td>White 1</td><td> 7,51 %</td><td> 97,7%</td><td> 0,86</td>
<td>White 2</td><td> 8,40%</td><td> 98,4%</td><td> 0,89</td>
<td>Problem 1</td><td> 2,61%</td><td> 94,14%</td><td> 5,60</td>
<td>Problem 2</td><td> 3,28%</td><td> 97,93%</td><td> 6,27</td>
As the results show, at gastric pH and for 2 hours (estimated duration of gastric digestion), only 7.96% ± 0.63 is recovered for the white and 2.95% ± 0.47 for the white. This is why it follows that sodium monofluorophosphate is hardly hydrolyzed at that pH, so the fluoride ion is not released in a significant amount, which is what reacts it with Ca<sup>2</sup>+ to form the insoluble salt CaF2. On the other hand, the fact that lower recovery values are obtained with respect to the blank in the test sample is due to the pH of the solution after two hours, which indicates that the kaolic salt present in the sample acted as an agent. buffering.
Example 1
Pharmaceutical composition containing cholecalciferol, alcoholic carbonate, sodium monofluorophosphate in the form of chewable tablets with a berry flavor.
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that obtained good organoleptic acceptance in tests with healthy volunteers:
<td>Cholecalciferol</td><td> 400</td>
<td>Sorbitol</td><td> 400.00</td>
<td>Aspartame</td><td> 10.00</td>
<td>L-HPC</td><td> 200.00</td>
<td>Sodium monofluorophosphate</td><td> 100.00</td>
<td>CaCO3 90% MD</td><td> 1666.67</td>
<td>Ac. Chotric</td><td> 50.00</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Forest fruit essence</td><td> 2.50</td>
Tablet breaking strength 10 kp, friability (% according to pharmacopoeia) 0.99%, friction friability 0.19%
Example 2
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium monofluorophosphate in the form of chewable tablets with orange flavor
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that obtained good organoleptic acceptance in tests with healthy volunteers:
ES 2 192 136 A1
<td>Cholecalciferol</td><td> 400</td>
<td>Sorbitol</td><td> 100.00</td>
<td>Aspartame</td><td> 10.00</td>
<td>L-HPC</td><td> 200.00</td>
<td>Sodium monofluorophosphate</td><td> 100.00</td>
<td>CaCO3 95% MD</td><td> 1580.00</td>
<td>Ac. Citric</td><td> 75.00</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Orange essence</td><td> 2.09</td>
Tablet breaking strength 7.3 kp, friability (% according to pharmacopoeia) 2.67%, friction friability 0.79%
Example 3
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium monofluorophosphate in the form of chewable tablets flavored with berries.
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that obtained good organoleptic acceptance in tests with healthy volunteers:
<td>Cholecalciferol</td><td> 800</td>
<td>Sorbitol</td><td> 400.00</td>
<td>Aspartame</td><td> 10.00</td>
<td>L-HPC</td><td> 200.00</td>
<td>Sodium monofluorophosphate</td><td> 100.00</td>
<td>CaCO3 90% MD</td><td> 1666.67</td>
<td>Ac. Citric</td><td> 50.00</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Forest fruit essence</td><td> 2.50</td>
Example 4
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium monofluorophosphate in the form of chewable tablets with orange flavor
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that obtained good organoleptic acceptance in tests with healthy volunteers:
<td>Cholecalciferol</td><td> 400</td>
<td>Sorbitol</td><td> 200.00</td>
<td>Aspartame</td><td> 10.00</td>
<td>L-HPC</td><td> 200.00</td>
<td>Sodium monofluorophosphate</td><td> 100.00</td>
<td>CaCO3 90% MD</td><td> 1666.67</td>
<td>Ac. Citric</td><td> 25.00</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Orange essences</td><td> 2.00</td>
Tablet breaking strength 10.02 kp, friability (% according to pharmacopoeia) 0.60%, friction friability 0.20%
ES 2 192 136 A1
Example 5
Pharmaceutical composition containing cholecalciferol, colic carbonate, sodium monofluorophosphate in the form of chewable tablets with orange flavor
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that obtained good organoleptic acceptance in tests with healthy volunteers:
<td>Cholecalciferol</td><td> 400</td>
<td>Sorbitol</td><td> 500.00</td>
<td>Aspartame</td><td> 5.00</td>
<td>Saccharin</td><td> 5.00</td>
<td>Lactose monohydrate</td><td> 67.00</td>
<td>Croscarmellose sodium</td><td> 30.00</td>
<td>Sodium monofluorophosphate</td><td> 100.00</td>
<td>CaCO3 90% MD</td><td> 1666.67</td>
<td>Magnesium stearate</td><td> 50.00</td>
<td>Orange essence</td><td> 2.30</td>
Tablet breaking strength 11.70 kp, frictional friability 0.84%
Example 6
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium monofluorophosphate in the form of chewable tablets with strawberry flavor
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that they obtained good organoleptic acceptance in tests with
<td colspan="2">healthy volunteers:</td>
<td>Cholecalciferol</td><td> 400</td>
<td>Sorbitol</td><td> 500.00</td>
<td>Aspartame</td><td> 5.00</td>
<td>Saccharin</td><td> 5.00</td>
<td>Lactose monohydrate</td><td> 67.00</td>
<td>Croscarmellose sodium</td><td> 30.00</td>
<td>Sodium monofluorophosphate</td><td> 75.00</td>
<td>CaCO3 90% MD</td><td> 1666.67</td>
<td>Magnesium stearate</td><td> 50.00</td>
<td>Strawberry essence</td><td> 2.30</td>
Example 7
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium monofluorophosphate in the form of effervescent tablets with orange flavor
Following the general technique for the preparation of effervescent tablets, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), which obtained good organoleptic acceptance in tests. with healthy volunteers:
ES 2 192 136 A1
<td>Kaolic citrate</td><td> 2280.00</td>
<td>Coalcium carbonate</td><td> 300.00</td>
<td>Sodium monofluorophosphate</td><td> 100.00</td>
<td>Cholecalciferol</td><td> 400</td>
<td>Saccharin</td><td> 15.00</td>
<td>Sodium bicarbonate</td><td> 200.00</td>
<td>TO<sup>or</sup> anhydrous choric acid</td><td> 400.00</td>
<td>Defoamer silicone</td><td> 3.20</td>
<td>Polyethylene Glycol 4000</td><td> 30.00</td>
<td>Scent of orange</td><td> 10.00</td>
Example 8
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium monofluorophosphate in the form of effervescent granules with orange flavor
Following the general technique for the preparation of this type of formulation, pharmaceutical compositions were prepared in the form of effervescent granules of the aforementioned active principles with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components by pharmaceutical form) , which obtained good organoleptic acceptance in trials with healthy volunteers:
<td>Calcium gluconate lactate</td><td> 2948.00</td>
<td>Coalcium carbonate</td><td> 300.00</td>
<td>Sodium monofluorophosphate</td><td> 100.00</td>
<td>Cholecalciferol</td><td> 400</td>
<td>Saccharin</td><td> 15.00</td>
<td>Sodium bicarbonate</td><td> 200.00</td>
<td>TO<sup>or</sup> choric acid monohydrate</td><td> 435.00</td>
<td>Defoamer silicone</td><td> 3.20</td>
<td>Scent of orange</td><td> 10.00</td>
Example 9
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of effervescent tablets with lemon flavor
Following the general technique for the preparation of effervescent tablets, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), which obtained good organoleptic acceptance in tests. with healthy volunteers. The sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula provided with a gastro-resistant coating.
<td>Kaolic citrate</td><td> 2280.00</td>
<td>Coalcium carbonate</td><td> 300.00</td>
<td>Sodium fluoride</td><td> 21.05</td>
<td>Cholecalciferol</td><td> 400</td>
<td>Saccharin</td><td> 15.00</td>
<td>Sodium bicarbonate</td><td> 200.00</td>
<td>TO<sup>or</sup> anhydrous choric acid</td><td> 400.00</td>
<td>Defoamer silicone</td><td> 3.20</td>
<td>Polyethylene Glycol 4000</td><td> 30.00</td>
<td>Ethylcellulose</td><td> 2.11</td>
<td>Lemon scent</td><td> 10.00</td>
ES 2 192 136 A1
Example 10
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of effervescent granules with orange flavor
Following the general technique for the preparation of this type of formulation, pharmaceutical compositions were prepared in the form of effervescent granules of the aforementioned active principles with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components by pharmaceutical form) , which obtained good organoleptic acceptance in tests with healthy volunteers.
The sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Calcium gluconate lactate</td><td> 2948.00</td>
<td>Calcium carbonate</td><td> 300.00</td>
<td>Soadic florur</td><td> 21.05</td>
<td>Saccharin</td><td> 15.00</td>
<td>Sodium bicarbonate</td><td> 200.00</td>
<td>TO<sup>to</sup> monohydrated caric acid</td><td> 435.00</td>
<td>Defoamer silicone</td><td> 3.20</td>
<td>Ethylcellulose</td><td> 2.11</td>
<td>Scent of orange</td><td> 10.00</td>
Example 11
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of chewable tablets flavored with berries.
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that they obtained good organoleptic acceptance in tests with healthy volunteers.
The sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Cholecalciferol</td><td> 400</td>
<td>Sorbitol</td><td> 400.00</td>
<td>Aspartame</td><td> 10.00</td>
<td>L-HPC</td><td> 200.00</td>
<td>TO<sup>to</sup> anhydrous catric acid</td><td> 50.00</td>
<td>Sodium fluoride</td><td> 21.05</td>
<td>CaCO3 90% MD</td><td> 1666.67</td>
<td>Ethylcellulose</td><td> 2.11</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Forest fruit essence</td><td> 2.50</td>
Example 12
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of chewable tablets with lemon flavor
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that they obtained good organoleptic acceptance in tests with healthy volunteers.
ES 2 192 136 A1
Sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Cholecalciferol</td><td> 400</td>
<td>Sorbitol</td><td> 400.00</td>
<td>Aspartame</td><td> 10.00</td>
<td>Croscarmellose sodium</td><td> 30.00</td>
<td>TO<sup>or</sup> anhydrous choric acid</td><td> 50.00</td>
<td>Sodium fluoride</td><td> 25.00</td>
<td>CaCO3 90% MD</td><td> 1666.67</td>
<td>L-HPC</td><td> 125.00</td>
<td>Ethylcellulose</td><td> 2.50</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Lemon essence</td><td> 1.23</td>
Tablet breaking strength 13.00 kp, friability (% according to pharmacopoeia) 0.90%, friction friability 0.47%
Example 13
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of chewable tablets with orange flavor
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that they obtained good organoleptic acceptance in tests with healthy volunteers.
Sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Cholecalciferol</td><td> 400</td>
<td>Xylitol</td><td> 400.00</td>
<td>Aspartame</td><td> 10.00</td>
<td>Sodium fluoride</td><td> 25.00</td>
<td>Coalcium phosphate</td><td> 1547.50</td>
<td>L-HPC</td><td> 200.00</td>
<td>Ethylcellulose</td><td> 3.75</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Orange essence</td><td> 2.09</td>
Tablet breaking strength 9.25 kp, friability (% according to pharmacopoeia) 1.02%, friction friability 0.63%
Example 14
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of chewable tablets flavored with berries.
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that they obtained good organoleptic acceptance in tests with healthy volunteers.
Sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula with a gastro-resistant coating.
ES 2 192 136 A1
<td>Calcic carbonate 90% MD</td><td> 1666.67</td>
<td>Sodium fluoride</td><td> 25.00</td>
<td>Cholecalciferol</td><td> 400</td>
<td>Fructose</td><td> 300.00</td>
<td>L-HPC</td><td> 150.00</td>
<td>Sorbitol</td><td> 100.00</td>
<td>Croscarmellose Sodium</td><td> 30.00</td>
<td>Aspartame</td><td> 5.00</td>
<td>Saccharin</td><td> 5.00</td>
<td>Ethylcellulose</td><td> 2.50</td>
<td>TO<sup>and</sup> stearic acid</td><td> 24.00</td>
<td>Forest fruit essence</td><td> 2.09</td>
Tablet breaking strength 9.75 kp, friability (% according to pharmacopoeia) 0.97%, friction friability 0.56%
Example 15
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of chewable tablets with orange flavor
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that they obtained good organoleptic acceptance in tests with healthy volunteers.
Sodium fluoride was previously treated with Eudragit RS 100® in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Cealcium phosphate</td><td> 1547.5</td>
<td>Cholecalciferol</td><td> 400</td>
<td>Xylitol</td><td> 400.00</td>
<td>Aspartame</td><td> 5.00</td>
<td>Saccharin</td><td> 5.00</td>
<td>L-HPC</td><td> 200.00</td>
<td>Sodium fluoride</td><td> 25.00</td>
<td>Eudragit RS 100®</td><td> 2.50</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Orange essence</td><td> 2.09</td>
Tablet breaking strength 13.50 kp, friability (% according to pharmacopoeia) 0.80%, friction friability 0.32%
Example 16
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of chewable tablets flavored with berries.
Following the general technique for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with adequate technical characteristics. and that they obtained good organoleptic acceptance in tests with healthy volunteers.
The sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula with a gastro-resistant coating.
ES 2 192 136 A1
<td>CaCO3 90 MD</td><td> 1666.67</td>
<td>Sodium fluoride</td><td> 25.00</td>
<td>Cholecalciferol</td><td> 800</td>
<td>Fructose</td><td> 300.00</td>
<td>L-HPC</td><td> 150.00</td>
<td>Sorbitol</td><td> 100.00</td>
<td>Croscarmellose sodium</td><td> 30.00</td>
<td>Aspartame</td><td> 5.00</td>
<td>Saccharin</td><td> 5.00</td>
<td>Ethylcellulose</td><td> 2.50</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Forest fruit essence</td><td> 2.09</td>
Tablet breaking strength 13.25 kp, friability (% according to pharmacopoeia) 0.78%, friction friability 0.37%
Example 17
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of chewable tablets with orange flavor
Following the general technique for for the preparation of chewable tablets by direct compression, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), with technical characteristics. adequate and that obtained good organoleptic acceptance in tests with healthy volunteers.
The sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Calcium phosphate</td><td> 1547.50</td>
<td>Cholecalciferol</td><td> 800</td>
<td>Mannitol</td><td> 400.00</td>
<td>Aspartame</td><td> 10.00</td>
<td>L-HPC</td><td> 200.00</td>
<td>Sodium fluoride</td><td> 25.00</td>
<td>Ethylcellulose</td><td> 2.50</td>
<td>Magnesium stearate</td><td> 24.00</td>
<td>Orange essence</td><td> 2.09</td>
Tablet breaking strength 9.50 kp, friability (% according to pharmacopoeia) 1.03%, friction friability 0.71%
Example 18
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of effervescent tablets with orange flavor
Following the general technique for the preparation of effervescent tablets, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), which obtained good organoleptic acceptance in tests. with healthy volunteers.
The sodium fluoride was previously treated with Eudragit RS 100® in order to incorporate it into the final formula with a gastro-resistant coating.
Caulcic lactate 3266.63
Sodium fluoride 25.00
Cholecalciferol 400
Potassium acesulfame 30.00
ES 2 192 136 A1
<td>Sodium bicarbonate</td><td> 200.00</td>
<td>TO<sup>or</sup> anhydrous choric acid</td><td> 300.00</td>
<td>TO<sup>or</sup> tartaric acid</td><td> 100.00</td>
<td>Defoamer silicone</td><td> 3.20</td>
<td>Polyethylene glycol 6000</td><td> 30.00</td>
<td>Orange scent</td><td> 3.00</td>
<td>Eudragit RS 100®</td><td> 2.50</td>
Example 19
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of effervescent tablets with orange flavor
Following the general technique for the preparation of effervescent tablets, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), which obtained good organoleptic acceptance in tests. with healthy volunteers.
Sodium fluoride was previously treated with Eudragit RS 100® in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Coalcium lactate</td><td> 3266.63</td>
<td>Sodium fluoride</td><td> 25.00</td>
<td>Cholecalciferol</td><td> 800</td>
<td>Potassium acesulfame</td><td> 30.00</td>
<td>Sodium bicarbonate</td><td> 200.00</td>
<td>TO<sup>or</sup> anhydrous choric acid</td><td> 300.00</td>
<td>TO<sup>or</sup> ascoorbic acid</td><td> 100.00</td>
<td>Defoamer silicone</td><td> 3.20</td>
<td>Polyethylene glycol 6000</td><td> 30.00</td>
<td>Orange scent</td><td> 3.00</td>
<td>Eudragit RS 100®</td><td> 2.50</td>
Example 20
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of effervescent tablets with lime-lime flavor
Following the general technique for the preparation of effervescent tablets, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), which obtained good organoleptic acceptance in tests. with healthy volunteers.
Sodium fluoride was previously treated with ethylcellulose in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Calcium gluconate lactate</td><td> 2948.00</td>
<td>Caolic carbonate</td><td> 300.00</td>
<td>Sodium fluoride</td><td> 21.05</td>
<td>Cholecalciferol</td><td> 400</td>
<td>Saccharin</td><td> 25.00</td>
<td>Sodium bicarbonate</td><td> 200.00</td>
<td>TO<sup>or</sup> choric acid monohydrate</td><td> 435.00</td>
<td>Defoamer silicone</td><td> 3.20</td>
<td>Ethylcellulose</td><td> 3.75</td>
<td>Lime lime scent</td><td> 7.50</td>
ES 2 192 136 A1
Example 21
Pharmaceutical composition containing cholecalciferol, calcium carbonate, sodium fluoride in the form of effervescent tablets with orange flavor
Following the general technique for the preparation of effervescent tablets, tablets of the aforementioned active principles were prepared with the indicated compositions (IU amounts for vitamin D and in milligrams for the rest of the components for each tablet), which obtained good organoleptic acceptance in tests. with healthy volunteers.
Sodium fluoride was previously treated with Eudragit RS 100® in order to incorporate it into the final formula with a gastro-resistant coating.
<td>Calcium gluconate lactate</td><td> 4645.14</td>
<td>Sodium fluoride</td><td> 25.00</td>
<td>Cholecalciferol</td><td> 400</td>
<td>Saccharin</td><td> 15.00</td>
<td>Aspartame</td><td> 15.00</td>
<td>Sodium bicarbonate</td><td> 200.00</td>
<td>TO<sup>or</sup> choric acid monohydrate</td><td> 435.00</td>
<td>Defoamer silicone</td><td> 3.20</td>
<td>Orange scent</td><td> 7.00</td>
<td>Eudragit RS 100®</td><td> 2.50</td>
Contents16
Every citation, both waysCites: the store holds 8 of 9
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| ES2255429A1 | Cited by | Spain | – | Search report |
| WO2006045870A1 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| WO0228401A1 | Cites | World Intellectual Property Organization (WIPO) | E | Search report |
| EP0455503A1 | Cites | European Patent Office (EPO) | X | Search report |
| EP1051976A2 | Cites | European Patent Office (EPO) | A | Search report |
| US3345265A | Cites | United States of America | A | Search report |
| US5228445A | Cites | United States of America | A | Search report |
| WO9631215A1 | Cites | World Intellectual Property Organization (WIPO) | X | Search report |
| WO9716193A1 | Cites | World Intellectual Property Organization (WIPO) | A | Search report |
| WO9906051A1 | Cites | World Intellectual Property Organization (WIPO) | A | Search report |
| [en línea][recuperado el 21.02.2003] Recuperado de: EPO EPODOC Database & CN 1177455 A (HONGQIAO HOSPITAL) 01.04.1998 (resumen) | Non-patent | – | – | Search report |
5 members in 3 offices
Priority claims2
| Document | Office | Kind | Date |
|---|---|---|---|
| 200200017 | Spain | A | |
| ES20020000017 | – | – | – |
Members5
| Document | Office | Kind | |
|---|---|---|---|
| WO03055500A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2003211610A1 | Australia | A1 | |
| ES2192136A1This record | Spain | A1 | |
| WO03055500A8 | World Intellectual Property Organization (WIPO) | A8 | |
| ES2192136B1 | Spain | B1 |
2 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Definitive protectionFG2A | FG2A | |
| Search report publishedEC2A | EC2A |
Numbers
- Publication
- 2192136
- Publication, DOCDB
- 2192136
- Publication, EPODOC
- ES2192136
- Application
- 17
- Application, DOCDB
- 200200017
- Application, EPODOC
- ES20020000017
Titles2
- Spanish
- COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO O PREVENCION DE LA OSTEOPOROSIS.
- English
- PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF OSTEOPOROSIS.
Classification
- CPC, 9
- A61K45/06
- A61K9/0056
- A61K9/2081
- A61K9/5026
- A61K31/592
- A61K31/593
- A61K33/06
- A61K33/16
- A61P19/10
- IPC, 9
- A61K9 00
- A61K9 20
- A61K9 50
- A61K31 592
- A61K31 593
- A61K33 06
- A61K33 16
- A61K45 06
- A61P19 10